bioatla.com (BCAB) - Gross Profit Margin

Official company branding of BioAtla, Inc. (BCAB)

BioAtla, Inc. (BCAB) maintains a high reputation for developing selective antibodies that reduce therapy toxicity. The change in gross margin visualizes this potential, where 19.90 serves as the current parameter value. Pricing power is secured by a unique drug activation system. An absolute patent moat and colossal FDA certification costs create insurmountable barriers for new market entrants.

BCAB (bioatla.com) Return on Gross Profit history from 07/04/2022 to 09/06/2026

Financial and market metric breakdowns for bioatla.com (BCAB)

- market price and analyst price targets:
Basic company analysis:BioAtla, Inc. (BCAB)
Manufactured products of BioAtla, Inc.

Gross margin determines production efficiency by measuring the portion of revenue remaining after direct costs, allowing investors to assess the business's actual operational margin of safety. The trend of the gross margin share of revenue reflects the ability of BioAtla, Inc. (BCAB) to monetize its proprietary oncology developments, confirming the brand's financial stability through high specialist trust and the uniqueness of its biologics.